Enter your information to understand your ANA levels.

The History of ANA Testing

The story of antinuclear antibody testing begins in 1948, when physician Malcolm Hargraves at the Mayo Clinic discovered what became known as the "LE cell" — a white blood cell seen under a microscope that had engulfed the nucleus of another cell, a strange phenomenon found almost exclusively in patients with lupus. This discovery proved for the first time that the immune system could attack a person's own cell nuclei, a foundational insight into autoimmune disease that reshaped how physicians understood conditions previously considered mysterious and poorly explained. Roughly a decade later, in 1957, researcher George Friou developed a far more sensitive technique called indirect immunofluorescence specifically to detect these antibodies, replacing the slow, subjective LE cell test with a method that could visualize antinuclear antibodies directly and reliably.

What ANA Actually Is

Antinuclear antibodies are not one single substance, but a broad category of antibodies that the immune system mistakenly produces against proteins found inside the nucleus of a person's own cells, rather than against outside invaders like bacteria or viruses. A positive result means these self-targeting antibodies are present in the blood, which is common in autoimmune diseases like lupus but can also appear, usually at lower levels, in other autoimmune conditions, certain infections, and even in some healthy people with no disease at all. Because of this, a positive ANA result is treated as a starting clue for further investigation rather than a diagnosis on its own, and doctors typically weigh the specific pattern and titer strength alongside a person's actual symptoms.

How ANA Is Measured

The reference method remains indirect immunofluorescence, in which a patient's blood serum is applied to a slide containing human cells — typically a laboratory-grown cell line called HEp-2, adopted widely since the mid-1970s for its clear, detailed nuclear structures. Any antinuclear antibodies present bind to the cell nuclei, and a second, fluorescently tagged antibody is added to make that binding visible under a specialized microscope. The resulting glow shows up in distinct visual patterns — speckled, homogeneous, or nucleolar, among others — that can hint at which specific autoimmune condition might be present, while faster automated tests using different chemistry are also common as an initial screening step before more detailed confirmatory testing follows.

Scientists Behind the Science

Malcolm Hargraves's 1948 discovery of the LE cell opened the door to understanding autoimmune disease as a process where the body's own defenses turn inward, a concept that seemed almost implausible to many physicians at the time it was first proposed. George Friou's development of immunofluorescence testing in the late 1950s turned that discovery into a practical, repeatable diagnostic tool still recognizable in laboratories today, decades later. The later adoption of the HEp-2 cell line as the standard testing substrate, established through the 1970s, dramatically improved the sensitivity and consistency of ANA testing compared to the animal-tissue sections originally used, a refinement that made the modern, standardized version of this test possible for clinics and hospitals everywhere it's ordered.